



Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

August 3, 2016

Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa, 50265
Community Room

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the Minutes
2. Commission Business
 - a) Annual Completion of Conflict of Interest Disclosure
 - b) Annual DUR Commission Chairperson and Vice Chairperson Elections
 - c) DHS Recommendation Letter – June 2016
3. IME Pharmacy Update
4. Updates/News Relevant to Medicaid
5. Prevalence Report Summary
6. Case Studies
7. Public Comment (See Conflict of Interest Disclosure Form)
8. Focus Studies/Provider Education Initiatives
 - a) Metoclopramide Utilization Greater than 90 Days – Follow Up
 - b) Modafinil Utilization in Members Under 21 Years of Age – Follow Up
 - c) Duplicate Antidepressants, Four or More Agents – Follow Up
 - d) Duplicate SSRIs – Follow Up
 - e) Duplicate SNRIs – Follow Up
 - f) Duplicate Antidepressants, SSRI plus SNRI – Follow Up
9. ProDUR Edits
 - a) Morphine Equivalent Dosing (MED) Limits

b) Loperamide Quantity Limits

10. Prior Authorization

- a) Lupron Depot Pediatric – Initial Review
- b) Lupron Depot Adult – Initial Review
- c) Short-Acting Opioids – Initial Review
- d) Buprenorphine/Naloxone – Initial Review
- e) Topical Acne and Rosacea Products (combination of Topical Anti-Acne Agents and Topical Retinoids) – Second Review
- f) NOACs (Removal and Combination of Criteria) – Second Review
- g) Patiromer (Veltassa) – Second Review
- h) Mepolizumab (Nucala™) – Second Review - Updated

11. Miscellaneous

- a) DUR Digest Vol. 29, No. 1 – Initial Review
- b) MedWatch

12. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting October 5, 2016***
Learning Resource Center, West Des Moines, IA**